Microsoft (NASDAQ: MSFT ) has become a bit of a soda jerk.
A couple of outlets dared to compare Microsoft's poorly received Windows 8 operating system -- and the company's reaction this past week in promising an update that will restore some missed features -- to Coca-Cola's (NYSE: KO ) flop with New Coke.
For those unfamiliar with the pop star's sugary blunder, Coca-Cola shocked the carbonated-beverage industry with the 1985 introduction of New Coke. The reformulation was a disaster, and the soft-drink titan responded quickly by bringing back the original beverage as Coca-Cola Classic.
"Microsoft is preparing to reverse course over key elements of its Windows 8 operating system, marking one of the most prominent admissions of failure for a new mass-market consumer product since Coca-Cola's New Coke fiasco nearly 30 years ago," the Financial Times wrote on Tuesday.
"The comparison with New Coke actually understates Microsoft's problem," The Economist followed, correctly arguing that Coke's solution was an easy fix. Some even speculated at the time that Coca-Cola did it on purpose, triggering a strong reaction from Coke-sipping loyalists.
Top 5 Promising Stocks To Own Right Now: Horsehead Holding Corp.(ZINC)
Horsehead Holding Corp., together with its subsidiaries, produces and sells specialty zinc and zinc-based products in North America. The company?s products include PW zinc metal, which is used to provide a protective coating to various fabricated products, including pipe and guard rails, heat exchangers, and telecommunications towers, as well as for the production of brass; and SSHG zinc metal that is used as feed for the manufacture of high-purity zinc powder and zinc alloys. It also offers zinc oxide for the production of tire and rubber products, chemicals, ceramics, plastics, paints, lubricating oils, and pharmaceuticals. In addition, the company recycles electric arc furnace dust, a hazardous waste generated by steel mini-mills. Further, it provides special zinc powders, which are used in general chemical and metallurgical applications, as well as in friction applications, such as brake linings for automobiles; battery grade zinc powders that are used in alkaline, me rcuric oxide, silver oxide, and zinc-air batteries; and copper-based powders, including brass, bronze, and nickel-silver powders, which are used in various applications comprising brazing, infiltrating, and powdered metallurgical hardware, such as lock bodies, valves, and gears. Additionally, the company offers short-line railroad service for the movement of materials. It primarily serves galvanizers and brass producers; alkaline battery industries; and manufacturers of tire and rubber products, lubricating oils, chemicals, paints, ceramics, plastics, and pharmaceuticals. The company was incorporated in 2003 and is based in Pittsburgh, Pennsylvania.
Advisors' Opinion:- [By Jake L'Ecuyer]
Leading and Lagging Sectors
Basic materials shares jumped about 1.72 percent in Monday's trading. Leading the sector was strength from Century Aluminum Co (NASDAQ: CENX) and Horsehead Holding (NASDAQ: ZINC). In trading on Monday, utilities shares dropped by 0.13 percent. - [By Jake L'Ecuyer]
Leading and Lagging Sectors
Basic materials shares jumped about 1.72 percent in Monday's trading. Leading the sector was strength from Century Aluminum Co (NASDAQ: CENX) and Horsehead Holding (NASDAQ: ZINC). In trading on Monday, utilities shares dropped by 0.13 percent.
Top 5 Promising Stocks To Own Right Now: Grillit Inc (GRLT)
Grillit Inc, formerly Holdings Energy Inc., incorporated on May 21, 2002, is a public corporation that discovers, invests and or acquires development-stage with solutions, clean technologies and eco-friendly products that serve the global alternative energy sector. The Company was formed to develop and engage in operations and management of digital wireless data communications services of 220 megahertz digital wireless data communications. In April 2013, the Company acquired Healthy & Tasty Ventures LLC. Effective December 19, 2013, GRILLiT Inc acquired a 10% interest in Natura Foods LLC.
Effective March 30, 2011, the Company had entered into a formal letter of intent with Remington Energy of Houston, Texas for the purchase of two oil and gas properties. On March 29, 2011, the Company disposed of its previous assets that represented the remaining business segment known as CX2 Technologies, Inc.
Advisors' Opinion:- [By Peter Graham]
Last Friday, small cap stocks Cambridge Heart, Inc (OTCMKTS: CAMH), Abby Inc (OTCMKTS: ABBY) and Grillit Inc (OTCMKTS: GRLT) surged 176.92%, 71.2% and 24.07%, respectively. Of course, that was last week and today is a new trading week. So what should investors and traders alike be prepared for this week with these three small caps? Here is a closer look to help you decide on an investing or trading strategy:
Top 5 Japanese Companies To Buy For 2015: Ishares Xinhua China 25 (FXI)
iShares FTSE/Xinhua China 25 Index Fund (the Fund) seeks investment results that correspond generally to the price and yield performance of the FTSE/Xinhua China 25 Index (the Index). The Index is designed to represent the performance of the largest companies in the China equity market that are available to international investors. The Index consists of Class H and Red Chip shares of 25 of the largest and most liquid Chinese companies. Securities in the Index are weighted based on the total market value of their shares. Each security in the Index is a constituent of the FTSE All-World Index. All of the securities in the Index trade on the Hong Kong Stock Exchange.
The Fund invests in a representative sample of securities included in the Index that collectively has an investment profile similar to the Index. The Fund�� investment advisor is Barclays Global Fund Advisors.
Advisors' Opinion:- [By Richard Schmidt]
iShares FTSE/Xinhua China (FXI) moved up about 10% in February. The strong move came as a result of a strong resurgence in China�� economic growth and its improved quality.
Top 5 Promising Stocks To Own Right Now: Genomic Health Inc (GHDX)
Genomic Health, Inc. (Genomic Health), incorporated in August 2000, is a molecular diagnostics company focused on the global development and commercialization of genomic-based clinical laboratory services that analyze the underlying biology of cancer allowing physicians and patients to make individualized treatment decisions. Its Oncotype DX platform utilizes quantitative genomic analysis known as reverse transcription polymerase chain reaction (RT-PCR), in standard tumor pathology specimens to provide tumor-specific information, or the oncotype of a tumor. As of February 2012, Oncotype DX was evaluated in invasive breast cancer in 13 clinical studies involving more than 4,000 breast cancer patients worldwide. Genomic Health offers its Oncotype DX tests as a clinical service, where it analyzes the expression levels of genes in tumor tissue samples and provide physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score, for invasive breast cancer and colon cancer and a DCIS Score for DCIS. Its Oncotype DX breast cancer test analyzes the expression levels of 21 genes and Oncotype DX colon cancer test analyzes the expression levels of 12 genes. In March 2012, the Company established a wholly owned subsidiary, InVitae Corporation.
Oncotype DX Platform
The Company�� Oncotype DX platform uses its RT-PCR approach to improve cancer treatment decisions. Its diagnostic approach correlates gene expression to clinical outcomes and provides an individualized analysis of each patient's tumor. The Company has built a diagnostic infrastructure that allows it to move from research into development through to processing actual patient samples in its clinical reference laboratory. The Company offers Oncotype DX tests as clinical laboratory services. Its technology allows the Company to analyze tumor tissue samples in its clinical reference laboratory and provide physicians with genomic information specific to the patient'! s tumor. It analyzes tissues that are handled, processed and stored under routine clinical pathology laboratory practices.
Oncotype DX Breast Cancer Test
To develop its Oncotype DX breast cancer test, the Company evaluated 250 genes in three independent clinical studies, which identified a 21-gene panel whose composite gene expression profile can be represented by a breast cancer Recurrence Score. The Company conducted studies of its Oncotype DX breast cancer test with clinical samples from postmenopausal women with invasive breast cancer who were treated with aromatase inhibitors. In March 2010, the Journal of Clinical Oncology published results from a European study using its test to analyze tumor samples from over 1,200 patients in the ATAC (Arimedix, Tamoxifen, Alone or in Combination) trial, which established the use of aromatase inhibitors for adjuvant treatment of postmenopausal women with hormone receptor-positive breast cancer. The study demonstrated that, along with other standard measures, such as tumor size, its Oncotype DX breast cancer test contributes independently to provide a more complete picture of prognosis for N- and N+ patients treated with aromatase inhibitors.
In December 2011, the Company presented positive results from the ECOG E5194 DCIS clinical validation study at SABCS. The study met its primary endpoint by demonstrating that a pre-specified Oncotype DX DCIS Score can predict the risk of local recurrence, defined as either the development of a new invasive breast cancer or the recurrence of DCIS in the same breast. In December 2011, the Company made Oncotype DX available for patients with ductal carcinoma in situ (DCIS), of the breast, a pre-invasive form of breast cancer. The launch of Oncotype DX for DCIS patients was based on positive results presented from a clinical validation study of Oncotype DX breast cancer test in patients with DCIS, conducted by the Eastern Cooperative Oncology Group (ECOG), a clinical trials cooperative! group su! pported by the National Cancer Institute.
Oncotype DX Colon Cancer Test
The Company developed its gene panel by identifying 761 cancer-related genes through review of existing research literature and computer analysis of genomic databases. The 761 candidate genes were also examined to determine whether they would be useful beyond other key variables including tumor stage, tumor grade, lymph nodes examined and MMR/MSI. It selected a final set of 12 genes, which were then independently evaluated in a validation study of over 1,400 stage II colon cancer patients from the Quick and Simple and Reliable (QUASAR), randomized study of adjuvant chemotherapy in the United Kingdom. This international, multi-center randomized trial examined the recurrence risk and the benefit associated with 5-fluorouracil/leucovorin, or 5FU/LV, adjuvant chemotherapy. Gene expression was quantified by RT-PCR from manually microdissected FPE primary colon cancer tissue, and recurrence-free interval, disease-free survival and overall survival were analyzed. In January 2012, the Company presented positive results of the first clinical decision making study of the Oncotype DX colon cancer test that shows that Recurrence Score result has a significant impact on treatment recommendations for stage II colon cancer patients.
The Company competes with General Electric Company, Hologic, Inc., Novartis AG, Myriad Genetics, Inc., Qiagen N.V., Response Genetics, Inc., Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Roche Holding, Ltd, Siemens AG and Johnson & Johnson.
Advisors' Opinion:- [By Sean Williams]
What: Shares of Genomic Health (NASDAQ: GHDX ) , a provider of genome-based clinical diagnostic tests, popped as much as 10% following the release of its first-quarter results.
- [By John Udovich]
Large and small cap cancer stocks Gilead Sciences, Inc (NASDAQ: GILD), Celgene Corporation (NASDAQ: CELG), Veracyte (NASDAQ: VCYT), Genomic Health, Inc (NASDAQ: GHDX), Cell Therapeutics Inc (NASDAQ: CTIC) and MetaStat Inc (OTCMKTS: MTST) have all been producing a steady stream of news lately for biotech investors looking for a way to cash in on the growth in development of�cancer treatments. Just consider the following news:
- [By John Udovich]
On Tuesday, small cap cancer diagnostic stock Myriad Genetics, Inc (NASDAQ: MYGN) jumped 11.42% in one day, meaning its worth taking a closer look at the stock along with the performance of small cap cancer diagnostic stocks like Rosetta Genomics Ltd (NASDAQ: ROSG) and�Genomic Health, Inc (NASDAQ: GHDX) plus mid cap diagnostic stock Quest Diagnostics Inc (NYSE: DGX). I should mention that we have had�Myriad Genetics in our SmallCap Network Elite Opportunity (SCN EO) portfolio since February 5th and we are already up 18.50%���a nice return in just two weeks time.
Top 5 Promising Stocks To Own Right Now: Kilroy Realty Corp (KRC)
Kilroy Realty Corporation, incorporated on September 13, 1996, is a self-administered real estate investment trust (REIT). The Company focuses on office and industrial submarkets along the West Coast. The Company owns, develops, acquires and manages real estate assets, consisting primarily of Class A real estate properties in the coastal regions of Los Angeles, Orange County, San Diego County, the San Francisco Bay Area and greater Seattle. As of December 31, 2011, the Company�� portfolio consisted of 104 office buildings (the Office Properties) and 39 industrial buildings (the Industrial Properties). The Company owns its interests in all of its Office Properties and Industrial Properties through the Kilroy Realty, L.P. (the Operating Partnership) and Kilroy Realty Finance Partnership, L.P. (the Finance Partnership). In March 2012, the Company purchased Menlo Corporate Center in Menlo Park, California. In June 2012, the Company purchased two office properties in the Lake Union submarket of Seattle. In January 2013, the Company purchsed Westlake Terry, a two building 320,399 square-foot office property. In September 2013, the Company announced it has completed the purchase of a 13.8 acre Class A office campus in the coastal Del Mar sub-market of San Diego. Effective September 19, 2013, Kilroy Realty Corp acquired The Heights, a owner and operator of an office campus. In January 2014, Kilroy Realty Corp completed the disposition of 13 San Diego office properties in two tranches. In January 2014, Kilroy Realty Corp acquired from The Academy of Motion Pictures Arts and Sciences an approximate four-acre parcel near the intersection of Sunset Boulevard and Vine Street in Hollywood.
On January 28, 2011, the Company acquired one building in 250 Brannan Street, San Francisco, CA. On April 21, 2011, the Company acquired four buildings in 10210, 10220 and 10230 NE Points Drive; 3933 Lake Washington Boulevard NE, Kirkland, WA. On May 12, 2011, the Company acquired one building in 10770 Water! idge Circle, San Diego, CA. On June 3, 2011, the Company acquired one building in 601 108th Avenue N.E., Bellevue, WA. On June 9, 2011, the Company acquired one building in 4040 Civic Center Drive, San Rafael, CA. On September 15, 2011, the Company acquired one building in 201 Third Street, San Francisco, CA. On November 15, 2011, the Company acquired one building in 301 Brannan Street, San Francisco, CA. On December 15, 2011, the Company acquired one building in 370 Third Street, San Francisco, CA. In December 2011, it commenced redevelopment at one of its acquired properties in San Francisco. On January 30, 2012, the Company sold 15004 Innovation Drive, San Diego, CA and 10243 Genetic Center Drive, San Diego, CA. In September 2011, the Company disposed of its interest in 10350 Barnes Canyon and 10120 Pacific Heights Drive, San Diego, CA. In December 2011, the Company disposed of interest in 2031 E. Mariposa Avenue, Los Angeles, CA.
The Company conducts substantially all of its operations through the Operating Partnership of which as of December 31, 2011, it owned a 97.2% general partnership interest. Kilroy Realty Finance, Inc., a wholly owned subsidiary of the Company, is the sole general partner of the Finance Partnership. The Company conducts substantially all of its development activities through Kilroy Services, LLC (KSLLC), which is a wholly owned subsidiary of the Operating Partnership. Its wholly owned subsidiaries include Kilroy Realty TRS, Inc., Kilroy Realty Management, L.P., Kilroy RB, LLC, Kilroy RB II, LLC, Kilroy Realty Northside Drive, LLC and Kilroy Realty 303, LLC. As of December 31, 2011, the Company�� tenants included Intuit, Inc., Bridgepoint Education, Inc., Delta Dental of California, AMN Healthcare, Inc., Hewlett-Packard Company, Fish & Richardson P.C., Scripps Health and Epson America, Inc.
Advisors' Opinion:- [By Rich Duprey]
Real estate investment trust�Kilroy Realty� (NYSE: KRC ) �announced yesterday�its second-quarter dividend of $0.35 per share, the same rate it's paid since 2009.
No comments:
Post a Comment